Genetically proxied therapeutic inhibition of lipid-lowering drug targets and risk of rheumatoid arthritis disease: a Mendelian randomization study

ConclusionsOur results do not provide evidence to support the hypothesis that reducing LDL-C levels with statins, alirocumab, or ezetimibe effectively prevents the risk of developing RA. However, our study provides valuable insights into the assessment of lipid-lowering agents in RA, which can enhance our understanding of the condition and assist in clinical practice by aiding in the determination and monitoring of RA status to clinical response.Key Points• Common lipid-lowering drugs such as statins, alirocumab, or evolocumab may not effectively prevent the development of rheumatoid arthritis.• This study provides clues for further exploration of the role of lipid-lowering therapy in other high-risk diseases, contributing to a deeper understanding of the potential effects of lipid-lowering treatment.
Source: Clinical Rheumatology - Category: Rheumatology Source Type: research